Our Science – Day Website
Patricia M. Day, Ph.D.
My major projects in LCO have involved applying cell biological techniques to questions of papillomavirus entry and early events in infection.
In one of my early studies in this area I defined the cellular pathway utilized by papillomaviruses for uptake and intracellular transport during the establishment of infection.
In a separate project, I developed an assay to evaluate viral uncoating by assessing antibody accessibility to the carboxyl terminus of L2 and the viral genome. This allowed me to determine that the minor capsid protein, L2, mediates the delivery of the genome to a transcriptionally active nuclear domain, ND10. I have found that intact ND10 are also critical for efficient establishment of infection.
I also demonstrated that the L2 capsid protein is modified by the cellular protease, furin during endocytosis. This cleavage is critical for the infectious process. In the absence of furin cleavage both the L2 protein and the genome are retained within the endosomal compartment. This was the first identification of a role for furin in the entry of any virus.
More recently I have evaluated the mechanism of neutralization of various monoclonal antibodies. This led to the understanding of which different regions of the capsid interact with either cell surface receptors or the extracellular matrix. I have also been evaluating conformational changes of the viral capsid that occur on the cell surface. I made a panel of monoclonal antibodies that recognize an open capsid conformation that occurs soon after cell binding. We are hopeful that these studies will lead to the development of a cross-neutralizing immunogen.
In addition to these projects within LCO, I have established collaborative projects with other NIH laboratories and also extramural laboratories. Currently I am collaborating with Ari Helenius at the Swiss Federal Institute of Technology in Zurich, to further investigate the endocytic pathway with a specific emphasis on cellular signaling molecules that are necessary for infection. Another current collaborative effort, with Richard Roden at Johns Hopkins University, involves the investigation of the mechanism of neutralization of anti-L2 monoclonal antibodies.
This page was last updated on 2/21/2013.